Chemours Company (The) (NYSE:CC) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Friday.

A number of other analysts have also recently issued reports on CC. Citigroup Inc. restated a “neutral” rating and set a $40.00 price objective (up from $34.00) on shares of Chemours Company (The) in a research report on Friday, April 14th. J P Morgan Chase & Co upgraded Chemours Company (The) from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $39.00 to $50.00 in a research report on Friday, May 12th. Susquehanna Bancshares Inc boosted their price objective on Chemours Company (The) from $45.00 to $55.00 and gave the company a “positive” rating in a research report on Monday, May 15th. ValuEngine upgraded Chemours Company (The) from a “hold” rating to a “buy” rating in a research report on Friday, June 2nd. Finally, UBS AG restated a “sell” rating and set a $36.00 price objective (up from $35.00) on shares of Chemours Company (The) in a research report on Wednesday, June 14th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Chemours Company (The) has a consensus rating of “Buy” and an average target price of $51.50.

Chemours Company (NYSE CC) traded up 3.85% during mid-day trading on Friday, hitting $46.12. 574,783 shares of the stock were exchanged. The company has a market cap of $8.52 billion, a P/E ratio of 30.18 and a beta of 3.63. Chemours Company has a one year low of $11.09 and a one year high of $51.51. The company has a 50-day moving average price of $43.25 and a 200-day moving average price of $37.90.

Chemours Company (The) (NYSE:CC) last released its quarterly earnings data on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.02. The business had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. Chemours Company (The)’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.27 earnings per share. On average, analysts predict that Chemours Company will post $3.51 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Chemours Company (The) (NYSE:CC) Cut to “Hold” at BidaskClub” was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/11/chemours-company-the-nysecc-cut-to-hold-at-bidaskclub.html.

In other Chemours Company (The) news, VP Erich Parker sold 4,908 shares of the company’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $45.53, for a total value of $223,461.24. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Paul Kirsch sold 19,036 shares of the company’s stock in a transaction on Monday, June 5th. The shares were sold at an average price of $41.42, for a total value of $788,471.12. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

A number of hedge funds have recently made changes to their positions in CC. Dimensional Fund Advisors LP boosted its stake in shares of Chemours Company (The) by 51.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 491,439 shares of the specialty chemicals company’s stock worth $10,856,000 after buying an additional 167,183 shares during the period. Teachers Advisors LLC boosted its stake in shares of Chemours Company (The) by 2.5% in the fourth quarter. Teachers Advisors LLC now owns 309,248 shares of the specialty chemicals company’s stock worth $6,831,000 after buying an additional 7,432 shares during the period. Cypress Capital Management LLC WY boosted its stake in shares of Chemours Company (The) by 1.9% in the first quarter. Cypress Capital Management LLC WY now owns 4,196 shares of the specialty chemicals company’s stock worth $162,000 after buying an additional 80 shares during the period. Oakbrook Investments LLC bought a new stake in shares of Chemours Company (The) during the first quarter worth $255,000. Finally, Retirement Systems of Alabama bought a new stake in shares of Chemours Company (The) during the first quarter worth $9,103,000. Hedge funds and other institutional investors own 75.21% of the company’s stock.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Analyst Recommendations for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.